Advertisement

What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?

      Since the introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors, the aim of this therapy has expanded from being solely a glucose-lowering treatment into also being organ protective even in people without diabetes. In this review, we present this evolution of the treatment principle, from early studies over randomized controlled trials. We discuss available real-world evidence and summarize a number of recent post hoc analyses from the randomized controlled trials with kidney end points. As the use of sodium-glucose cotransporter 2 inhibitors becomes more widespread, new questions arise regarding initiation and follow-up, which we try to answer by providing the currently available data. For translation of study results to global effects, implementation becomes important. As is often the case, this does not happen without barriers, which must be addressed and handled. Finally, future studies and populations are discussed because it may well be that sodium-glucose cotransporter 2 inhibition are expanding into further areas.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Petrykiv S.
        • Sjöström C.D.
        • Greasley P.J.
        • Xu J.
        • Persson F.
        • Heerspink H.J.L.
        Differential effects of dapagliflozin on cardiovascular risk factors at Varying Degrees of renal function.
        Clin J Am Soc Nephrol. 2017; 12: 751-759
        • Heerspink H.J.L.
        • Desai M.
        • Jardine M.
        • Balis D.
        • Meininger G.
        • Perkovic V.
        Canagliflozin Slows progression of renal function decline independently of glycemic effects.
        J Am Soc Nephrol. 2017; 28: 368-375
        • Dekkers C.C.J.
        • Wheeler D.C.
        • Sjöström C.D.
        • Stefansson B.V.
        • Cain V.
        • Heerspink H.J.L.
        Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
        Nephrol Dial Transpl. 2018; 33: 1280
        • Heerspink H.J.L.
        • Greene T.
        • Tighiouart H.
        • et al.
        • Chronic Kidney Disease Epidemiology C
        Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.
        Lancet Diabetes Endocrinol. 2019; 7: 128-139
        • Wanner C.
        • Inzucchi S.E.
        • Lachin J.M.
        • et al.
        Empagliflozin and progression of kidney disease in type 2 diabetes.
        N Engl J Med. 2016; 375: 323-334
        • Cherney D.Z.I.
        • Zinman B.
        • Inzucchi S.E.
        • et al.
        Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
        Lancet Diabetes Endocrinol. 2017; 5: 610-621
        • Wanner C.
        • Heerspink H.J.L.
        • Zinman B.
        • et al.
        Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG outcome trial.
        J Am Soc Nephrol. 2018; 29: 2755-2769
        • Perkovic V.
        • de Zeeuw D.
        • Mahaffey K.W.
        • et al.
        Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
        Lancet Diabetes Endocrinol. 2018; 6: 691-704
        • Mosenzon O.
        • Wiviott S.D.
        • Cahn A.
        • et al.
        Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
        Lancet Diabetes Endocrinol. 2019; 7: 606-617
        • Li C.X.
        • Liang S.
        • Gao L.
        • Liu H.
        Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis.
        PloS one. 2021; 16: e0244689
        • Fadini G.P.
        • Solini A.
        • Manca M.L.
        • et al.
        Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: a multicentre retrospective study.
        Diabetes Obes Metab. 2019; 21: 252-260
        • Kobayashi K.
        • Toyoda M.
        • Kimura M.
        • et al.
        Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
        Diabetes Vasc Dis Res. 2019; 16: 103-107
        • Zhou F.L.
        • Watada H.
        • Tajima Y.
        • et al.
        Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): a retrospective analysis of a Japanese commercial medical database.
        Diabetes Obes Metab. 2019; 21: 1925-1934
        • Heerspink H.J.L.
        • Karasik A.
        • Thuresson M.
        • et al.
        Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
        Lancet Diabetes Endocrinol. 2020; 8: 27-35
        • Perkovic V.
        • Jardine M.J.
        • Neal B.
        • et al.
        Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
        N Engl J Med. 2019; 380: 2295-2306
        • Fried L.F.
        • Emanuele N.
        • Zhang J.H.
        • et al.
        Combined Angiotensin inhibition for the treatment of diabetic nephropathy.
        N Engl J Med. 2013; 369: 1892-1903
        • Parving H.H.
        • Brenner B.M.
        • McMurray J.J.
        • et al.
        Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
        N Engl J Med. 2012; 367: 2204-2213
        • Mann J.F.
        • Schmieder R.E.
        • McQueen M.
        • et al.
        Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
        Lancet. 2008; 372: 547-553
        • Neuen B.L.
        • Young T.
        • Heerspink H.J.L.
        • et al.
        SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
        Lancet Diabetes Endocrinol. 2019; 7: 845-854
        • Heerspink H.J.L.
        • Stefansson B.V.
        • Correa-Rotter R.
        • et al.
        Investigators. Dapagliflozin in patients with chronic kidney disease.
        N Engl J Med. 2020; 383: 1436-1446
        • McMurray J.J.V.
        • Solomon S.D.
        • Inzucchi S.E.
        • et al.
        Dapagliflozin in patients with heart failure and reduced Ejection Fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Wheeler D.C.
        • Stefánsson B.V.
        • Jongs N.
        • et al.
        Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
        Lancet Diabetes Endocrinol. 2021; 9: 22-31
        • McMurray J.J.V.
        • Wheeler D.C.
        • Stefánsson B.V.
        • et al.
        Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease.
        Circulation. 2021; 143: 438-448
        • Bakris G.
        • Oshima M.
        • Mahaffey K.W.
        • et al.
        Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m(2): subgroup Analysis of the randomized CREDENCE trial.
        Clin J Am Soc Nephrol. 2020; 15: 1705-1714
        • Cannon C.P.
        • Perkovic V.
        • Agarwal R.
        • et al.
        Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial.
        Circulation. 2020; 141: 407-410
        • Jardine M.
        • Zhou Z.
        • Lambers Heerspink H.J.
        • et al.
        Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a CREDENCE secondary analysis.
        Clin J Am Soc Nephrol. 2021; 16: 384-395
        • Jardine M.J.
        • Zhou Z.
        • Mahaffey K.W.
        • et al.
        Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial.
        J Am Soc Nephrol. 2020; 31: 1128-1139
        • Ye N.
        • Jardine M.J.
        • Oshima M.
        • et al.
        Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: Insights from the CREDENCE trial.
        Circulation. 2021; 143: 1735-1749
        • Oshima M.
        • Jardine M.J.
        • Agarwal R.
        • et al.
        Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
        Kidney Int. 2021; 99: 999-1009
        • Kraus B.J.
        • Weir M.R.
        • Bakris G.L.
        • et al.
        Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
        Kidney Int. 2021; 99: 750-762
        • Oshima M.
        • Neuen B.L.
        • Li J.
        • et al.
        Early change in albuminuria with canagliflozin Predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial.
        J Am Soc Nephrol. 2020; 31: 2925-2936
        • Persson F.
        • Bain S.C.
        • Mosenzon O.
        • et al.
        Changes in albuminuria Predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER trial.
        Diabetes Care. 2021; 44: 1020-1026
        • Gadzhanova S.
        • Pratt N.
        • Roughead E.
        Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program.
        Diabetes Res Clin Pract. 2017; 130: 180-185
        • Dave C.V.
        • Schneeweiss S.
        • Patorno E.
        Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.
        Diabetes Obes Metab. 2019; 21: 434-438
        • Adimadhyam S.
        • Schumock G.T.
        • Calip G.S.
        • Smith Marsh D.E.
        • Layden B.T.
        • Lee T.A.
        Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis.
        Br J Clin Pharmacol. 2019; 85: 160-168
        • O’Donoghue M.L.
        • Kato E.T.
        • Mosenzon O.
        • et al.
        The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
        Diabetologia. 2021; 64: 1226-1234
        • Qiu M.
        • Ding L.
        • Wei X.
        • Wei W.
        • Zhou H.
        Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: a meta-analysis.
        Medicine (Baltimore). 2020; 99: e23489
        • de Boer I.H.
        • Caramori M.L.
        • Chan J.C.N.
        • et al.
        KDIGO 2020 clinical practice guideline for diabetes Management in chronic kidney disease.
        Kidney Int. 2020; 98: S1-S115
        • Buse J.B.
        • Wexler D.J.
        • Tsapas A.
        • et al.
        2019 Update to: Management of Hyperglycemia in type 2 diabetes, 2018. A Consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD).
        Diabetes Care. 2020; 43: 487-493
        • Tuttle K.R.
        • Brosius 3rd, F.C.
        • Cavender M.A.
        • et al.
        SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a Scientific Workshop Sponsored by the national kidney Foundation.
        Diabetes. 2021; 70: 1-16
      1. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet. 2020; 395: 709-733
        • McEwan P.
        • Bennett H.
        • Khunti K.
        • et al.
        Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence.
        Diabetes Obes Metab. 2020; 22: 2364-2374
        • Willis M.
        • Nilsson A.
        • Kellerborg K.
        • et al.
        Cost-effectiveness of canagliflozin added to Standard of care for treating diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM) in England: Estimates using the CREDEM-DKD model.
        Diabetes Ther. 2021; 12: 313-328
        • Herrington W.G.
        • Preiss D.
        • Haynes R.
        • et al.
        The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
        Clin Kidney J. 2018; 11: 749-761
        • Heerspink H.J.L.
        • Parving H.H.
        • Andress D.L.
        • et al.
        Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
        Lancet. 2019; 393: 1937-1947
        • Bakris G.L.
        • Agarwal R.
        • Anker S.D.
        • et al.
        Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.
        N Engl J Med. 2020; 383: 2219-2229